BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 35551655)

  • 1. Development of Cancer Immunotherapies.
    DeLucia DC; Lee JK
    Cancer Treat Res; 2022; 183():1-48. PubMed ID: 35551655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy.
    Carlson RD; Flickinger JC; Snook AE
    Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32283684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular insights into the development of T cell-based immunotherapy for prostate cancer.
    Dong B; Minze LJ; Xue W; Chen W
    Expert Rev Clin Immunol; 2014 Nov; 10(11):1547-57. PubMed ID: 25259804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for the Treatment of Urothelial Carcinoma.
    Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
    J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
    Ă–zdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
    Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy: sipuleucel-T and beyond.
    Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
    Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy.
    Nakajima H; Nakatsura T
    Immunol Med; 2021 Mar; 44(1):10-15. PubMed ID: 32643578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
    Laccetti AL; Subudhi SK
    Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
    Patel A; Fong L
    Oncology (Williston Park); 2018 Mar; 32(3):112-20. PubMed ID: 29548065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
    Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
    Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell Fate Reprogramming in the Era of Cancer Immunotherapy.
    Zimmermannova O; Caiado I; Ferreira AG; Pereira CF
    Front Immunol; 2021; 12():714822. PubMed ID: 34367185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.
    Singh BH; Gulley JL
    Asian J Androl; 2014; 16(3):364-71. PubMed ID: 24435055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond sipuleucel-T: immune approaches to treating prostate cancer.
    Cheng ML; Fong L
    Curr Treat Options Oncol; 2014 Mar; 15(1):115-26. PubMed ID: 24402184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate Cancer Immunotherapy-Finally in From the Cold?
    Runcie KD; Dallos MC
    Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer immunotherapy.
    McNeel DG
    Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A New Era of Immunotherapy in Prostate Cancer.
    Pizzola C; Rizvi SM; Joshi M
    Curr Mol Pharmacol; 2016; 9(3):217-225. PubMed ID: 26177645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.
    Lohmueller J; Finn OJ
    Pharmacol Ther; 2017 Oct; 178():31-47. PubMed ID: 28322974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.